NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1
Authors:
- 22 May 2022
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 118, 106869
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research Society
- Leukemia and Lymphoma Society of Canada
This publication has 19 references indexed in Scilit:
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsBlood, 2015
- Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1Annals of Hematology, 2014
- Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemiaLaboratory Investigation, 2013
- Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal CytogeneticsPLOS ONE, 2012
- Influence of FLT3‐internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate‐risk karyotype acute myeloid leukemiaCancer, 2012
- Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasmsLeukemia, 2011
- The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational statusBlood, 2010
- Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AMLLeukemia, 2010
- Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)Blood, 2010